Cellular subsets transfused
| . | Prophylactic granulocyte transfusions: cohort A . | No prophylactic granulocyte transfusions: cohort B . | P* . | ||
|---|---|---|---|---|---|
| No. . | Median, × 107 (range) . | No. . | Median, × 107 (range) . | ||
| Neutrophils | 77 | 220.70 (8.60-645.0) | 131 | 30.8 (0.06-636.0) | < .0001 |
| MNCs | 77 | 76.73 (19.56-244.9) | 132 | 70.02 (0.79-256.0) | .41 |
| CD34+ | 82 | 0.78 (0.05-7.50) | 132 | 0.79 (0.02-4.65) | .95 |
| CD3+ | 63 | 25.83 (7.56-67.97) | 121 | 19.6 (0.20-130.0) | .012 |
| CD4+ | 63 | 18.47 (3.59-58.97) | 121 | 15.1 (0.10-75.10) | .047 |
| CD8+ | 63 | 5.79 (1.19-33.45) | 121 | 3.55 (0.04-51.42) | .011 |
| CD19+ | 63 | 8.53 (1.49-47.47) | 121 | 6.97 (0.03-71.70) | .34 |
| CD16+CD56+ | 63 | 4.64 (0.10-15.50) | 121 | 3.23 (0.01-52.4) | .014 |
| . | Prophylactic granulocyte transfusions: cohort A . | No prophylactic granulocyte transfusions: cohort B . | P* . | ||
|---|---|---|---|---|---|
| No. . | Median, × 107 (range) . | No. . | Median, × 107 (range) . | ||
| Neutrophils | 77 | 220.70 (8.60-645.0) | 131 | 30.8 (0.06-636.0) | < .0001 |
| MNCs | 77 | 76.73 (19.56-244.9) | 132 | 70.02 (0.79-256.0) | .41 |
| CD34+ | 82 | 0.78 (0.05-7.50) | 132 | 0.79 (0.02-4.65) | .95 |
| CD3+ | 63 | 25.83 (7.56-67.97) | 121 | 19.6 (0.20-130.0) | .012 |
| CD4+ | 63 | 18.47 (3.59-58.97) | 121 | 15.1 (0.10-75.10) | .047 |
| CD8+ | 63 | 5.79 (1.19-33.45) | 121 | 3.55 (0.04-51.42) | .011 |
| CD19+ | 63 | 8.53 (1.49-47.47) | 121 | 6.97 (0.03-71.70) | .34 |
| CD16+CD56+ | 63 | 4.64 (0.10-15.50) | 121 | 3.23 (0.01-52.4) | .014 |
Data analysis for cellular subsets was limited to those patients for whom complete subset data were available. Data shown represent the total number of designated cells present in the granulocyte transfusion and the PBSCs (cohort A) or in the PBSCs alone (cohort B). All figures are per kilogram of recipient body weight.
Wilcoxon Mann-Whitney test.